A phase 3 study of gemcitabine and S-1 compared with gemcitabine monotherapy in patients with unresectable advanced pancreatic cancer.
Not Applicable
Completed
- Conditions
- pancreatic cancer
- Registration Number
- JPRN-UMIN000002244
- Lead Sponsor
- Chiba Cancer Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
(1)severe concurrent disease, (2)interstitial pneumonia, (3)massive abdominal or pleural effision (4)mental disoeder, (5)active concomitant malignancy, (6)severe diarrhea, (7)brain metastasis, (8)severe drug hypersensitibity, (9)pregnant or lactating females, (10)regular use of phenytoin, warfarin or frucitocin, (11)inappropriate for entry onto the study, as diagnosed by primary physician.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method progression free survival
- Secondary Outcome Measures
Name Time Method